{"meshTagsMajor":["Neoadjuvant Therapy"],"meshTags":["Adenocarcinoma","Antineoplastic Agents","Antineoplastic Agents, Phytogenic","Antineoplastic Combined Chemotherapy Protocols","Carboplatin","Carcinoma, Non-Small-Cell Lung","Humans","Lung Neoplasms","Lymph Node Excision","Lymphatic Metastasis","Male","Middle Aged","Neoadjuvant Therapy","Neoplasm Staging","Paclitaxel","Pneumonectomy","Radiotherapy, Adjuvant","Time Factors"],"meshMinor":["Adenocarcinoma","Antineoplastic Agents","Antineoplastic Agents, Phytogenic","Antineoplastic Combined Chemotherapy Protocols","Carboplatin","Carcinoma, Non-Small-Cell Lung","Humans","Lung Neoplasms","Lymph Node Excision","Lymphatic Metastasis","Male","Middle Aged","Neoplasm Staging","Paclitaxel","Pneumonectomy","Radiotherapy, Adjuvant","Time Factors"],"genes":["IIIA N2 NSCLC"],"organisms":["9606"],"publicationTypes":["Case Reports","Comparative Study","Journal Article"],"abstract":"Neoadjuvant chemotherapy before surgical resection of locally advanced non-small cell lung cancer (NSCLC) has been shown to improve survival compared with surgery alone in several randomized clinical trials. A case report is presented describing the use of paclitaxel and carboplatin in a multimodality regimen for a patient with stage IIIA N2 NSCLC. Studies are ongoing to determine the optimal type and timing of chemotherapy.","title":"Clinical presentation of stage IIIA (N2) non-small cell lung cancer: role of multimodality therapy.","pubmedId":"10619518"}